WHO Recommends Two New Candidate Vaccines for Ebola Trial in the DRC

November 5, 2026 • PressClubAi • 2 weeks ago • 2 min read

Places named in this headline: Democratic Republic of the Congo

Expert groups convened by the World Health Organization (WHO) have recommended adding two new candidate vaccines to the ongoing Tumaini clinical trial in the Democratic Republic of the Congo (DRC) to evaluate their protection against the Bundibugyo virus. The recommendation, issued this week, marks the first time vaccines targeting this specific virus are being evaluated during an active disease outbreak.

The two candidate vaccines recommended for clinical evaluation are ChAdOx1, developed by the University of Oxford and the Serum Institute of India, and Moderna’s mRNA-1469. According to the WHO, its independent Technical Advisory Group on Candidate Vaccines Prioritization made the selection based on available preclinical and early clinical data. Both candidates are set to be integrated into the trial pending national regulatory approvals.

The Tumaini trial is led by the DRC's Institut National de Recherche Biomédicale, with backing from the University of Antwerp, WHO, Epicentre, Médecins Sans Frontières, the Institute of Tropical Medicine of Antwerp, the Africa Centres for Disease Control and Prevention, and the Coalition for Epidemic Preparedness Innovations.

The trial utilizes a ring-vaccination strategy, administering candidates to contacts of individuals with confirmed Bundibugyo virus disease, as well as contacts of those who have died from the infection. Four vaccination rings have been established, with additional rings in preparation. The trial is also evaluating Ervebo to determine its efficacy against the Bundibugyo strain.

In addition to vaccine evaluations, therapeutics are being tested under the WHO-sponsored PARTNERS trial launched in July. That trial is assessing the monoclonal antibody MBP134, the antiviral remdesivir, and combination treatments, with plans to add maftivimab. A separate study is reviewing obeldevisir for post-exposure prophylaxis.

The WHO stated that preliminary findings from the therapeutic trials are expected in the coming months, while results from the vaccine trial are anticipated in early 2027.

Source

Based on material from Read source material

ReliefWeb

Republished source material reliefweb.int

This site republishes material from other organisations. Check the linked page for the original issuer.

How PressClub produces articles

PressClub uses AI to write news from collected source material, with formatted source text as a fallback. The linked material provides the source’s account; this article does not establish independent verification. Read the source for its own wording and updates.

Keep Going

Read next

Catch up with a briefing, browse more stories, or share this article.

Briefing Read the latest briefing Catch the bigger picture in one recap. Coverage Explore coverage Find topics receiving more reports than usual.
Continue reading

More news to read

Browse more published news. The topic labels show what each article covers.

Browse this topic